ReviewWIREs mechanisms of disease2022
Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam.
Review in WIREs mechanisms of disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.Antimicrobial resistance and infection control · 2025Pooled it
- Deciphering the Genetic Mechanisms Driving Carbapenem Resistance: A Multicenter Study from Seven Egyptian Governorates Using Multiplex PCR and Whole Genome Sequencing.Current microbiology · 2026Article
- Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers.Antimicrobial agents and chemotherapy · 2026Article
- The resistance mechanisms and risk factors of carbapenem-resistant Klebsiella pneumoniae to ceftazidime-avibactam.BMC research notes · 2026Article
- Monoclonal outbreak caused by ceftazidime-avibactam resistant blaGMS hygiene and infection control · 2026Article
- Genomic characterization of ceftazidime/avibactam-resistantFrontiers in microbiology · 2026Article
- Spotlight commentary: Treatment of multidrug-resistant Gram-negative infections in the era of growing antimicrobial resistance.British journal of clinical pharmacology · 2025Article
- The bacterial etiology and antimicrobial susceptibility of lower respiratory tract infections in Vietnam.Annals of clinical microbiology and antimicrobials · 2025Article
- Molecular Epidemiology of Carbapenem-ResistantMicroorganisms · 2025Article
- Article
- Genomic and molecular characterization of a ceftazidime-avibactam resistant Klebsiella pneumoniae strain isolated from a Chinese tertiary hospital.BMC microbiology · 2025Article
- Phenotypic Ultra-Rapid Antimicrobial Susceptibility Testing for Ceftazidime-Avibactam: In Support of Antimicrobial Stewardship.Microorganisms · 2025Article
- Molecular characterization of carbapenem resistance mechanisms and phenotypic correlations in clinicalFrontiers in microbiology · 2025Article
- Transmission of ceftazidime-avibactam-resistantBiosafety and health · 2024Article
- Pharmacokinetic/pharma-codynamic study of pralurbactam (FL058) combined with meropenem in a neutropenic murine thigh infection model.Frontiers in microbiology · 2024Article
- Overexpression of KPC contributes to ceftazidime-avibactam heteroresistance in clinical isolates of carbapenem-resistantFrontiers in cellular and infection microbiology · 2024Article
- A Novel Variant of KPC-179 Conferring Ceftazidime-Avibactam Resistance in a Carbapenem-ResistantInfection and drug resistance · 2024Article
- Synergistic Effect of Ceftazidime-Avibactam with Aztreonam on Carbapenemase-PositiveInfection and drug resistance · 2024Article
- Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae.Emerging infectious diseases · 2023Article
- Characterization of Carbapenemase- and ESBL-Producing Gram-Negative Bacilli Isolated from Patients with Urinary Tract and Bloodstream Infections.Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel β-lactamase inhibitor (avibactam) that has been approved by the U.S. Food and Drug Administration, the European Union, and the National Regulatory Administration in China. CAZ/AVI is used mainly to treat complicated urinary tract infections and complicated intra-abdominal infections in adults, as well as to treat patients infected with Carbapenem-resistant Enterobacteriaceae (CRE) susceptible to CAZ/AVI. However, increased clinical application of CAZ/AVI has resulted in the development of resistant strains. Mechanisms of resistance in most of these strains have been attributed to bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.